Business Description
Absci Corp
NAICS : 325412
SIC : 2834
ISIN : US00091E1091
Total Employee Number:
140Description
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 28.47 | |||||
Equity-to-Asset | 0.88 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.04 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 43.37 | |||||
Beneish M-Score | -4.87 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -31.8 | |||||
3-Year EBITDA Growth Rate | 9.1 | |||||
3-Year EPS without NRI Growth Rate | 8.9 | |||||
3-Year FCF Growth Rate | 13.8 | |||||
3-Year Book Growth Rate | -25.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 5.74 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 164.34 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 42.72 | |||||
9-Day RSI | 56.33 | |||||
14-Day RSI | 61.16 | |||||
3-1 Month Momentum % | 114.09 | |||||
6-1 Month Momentum % | 91.3 | |||||
12-1 Month Momentum % | 133.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.59 | |||||
Quick Ratio | 6.59 | |||||
Cash Ratio | 6.28 | |||||
Days Sales Outstanding | 204.37 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -17.9 | |||||
Shareholder Yield % | -3.44 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -7000.82 | |||||
Net Margin % | -6450.76 | |||||
EBITDA Margin % | -5816.94 | |||||
FCF Margin % | -5365.2 | |||||
OCF Margin % | -5304.63 | |||||
ROE % | -62.74 | |||||
ROA % | -53.87 | |||||
ROIC % | -157.59 | |||||
3-Year ROIIC % | 26.81 | |||||
ROC (Joel Greenblatt) % | -455.83 | |||||
ROCE % | -61.04 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 815.38 | |||||
PB Ratio | 9.55 | |||||
Price-to-Tangible-Book | 12.46 | |||||
EV-to-EBIT | -14.17 | |||||
EV-to-EBITDA | -15.68 | |||||
EV-to-Revenue | 911.96 | |||||
EV-to-Forward-Revenue | 337.67 | |||||
EV-to-FCF | -17 | |||||
Price-to-GF-Value | 11.39 | |||||
| Price-to-Net-Current-Asset-Value | 15.14 | |||||
| Price-to-Net-Cash | 16.05 | |||||
Earnings Yield (Greenblatt) % | -7.06 | |||||
FCF Yield % | -5.49 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ABSI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Absci Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.836 | ||
| EPS (TTM) ($) | -0.83 | ||
| Beta | 3.5294 | ||
| 3-Year Sharpe Ratio | 0.97 | ||
| 3-Year Sortino Ratio | 2.77 | ||
| Volatility % | 109.96 | ||
| 14-Day RSI | 61.16 | ||
| 14-Day ATR ($) | 0.986929 | ||
| 20-Day SMA ($) | 9.543 | ||
| 12-1 Month Momentum % | 133.7 | ||
| 52-Week Range ($) | 2.24 - 12.055 | ||
| Shares Outstanding (Mil) | 169.4 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Absci Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Absci Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-12 16:30 | In 125 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 124 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-12 16:30 | In 33 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 32 days | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-10 15:20 | 6.83 (+1.79%) | ||
| General meeting for 2026 | 2026-06-04 09:00 | 5.94 (-5.86%) | ||
| Guidance call for 2026 | 2026-06-03 07:35 | 6.35 (-2.01%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 16:30 | 5.95 (+6.44%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 5.95 (+6.44%) | ||
| 25th Annual Needham Virtual Healthcare Conference | 2026-04-16 13:30 | 3.17 (+0.32%) |
Show
Entries
Absci Corp Frequently Asked Questions
What is Absci Corp(ABSI)'s stock price today?
The current price of ABSI is $10.60. The 52 week high of ABSI is $12.06 and 52 week low is $2.24.
When is next earnings date of Absci Corp(ABSI)?
The next earnings date of Absci Corp(ABSI) is 2026-08-12 Est..
Does Absci Corp(ABSI) pay dividends? If so, how much?
Absci Corp(ABSI) does not pay dividend.
Guru Commentaries on NAS:ABSI
No articles.
Press Release
Articles on Absci Corp
Headlines
See More- 1
Jun 24, 2026
At a glance: stocks gapping up premarket
Seeking Alpha • 5:52am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers